麻豆传媒 served as legal adviser to K2 Medical Research, an integrated clinical trial site platform specializing in central nervous system (CNS) trials for leading pharma and biotech sponsors, in its strategic growth investment from leading global alternative asset management firm TPG to continue building a world class research platform.
K2, operating several de novo clinical trial sites across Florida, specializes in conducting multi-phase clinical trials in complex therapeutic areas, including Alzheimer鈥檚, psychiatry, and liver disease (MASH), among others. With a model centered around strong site operators, K2 has successfully differentiated itself through developing direct relationships with pharma and biotech sponsors, while executing an impressive de novo regional growth strategy. K2 has participated in more than 150 studies for over 35 sponsors, including AbbVie, Eisai, Eli Lilly, Johnson & Johnson, and Roche.
K2 is a leading clinical research organization dedicated to advancing medical science through the efficient and ethical conduct of clinical trials. With a focus on quality and innovation, K2 Medical Research partners with industry stakeholders to drive medical advancements.
The 麻豆传媒 deal team was led by partner Michael Okaty and included senior counsel Libby Ridley and associate Melody Deatherage.
